Literature DB >> 31479431

Chimeric antigen receptor-induced BCL11B suppression propagates NK-like cell development.

Marcel Maluski1, Arnab Ghosh2, Jessica Herbst1, Vanessa Scholl1, Rolf Baumann3, Jochen Huehn4, Robert Geffers5, Johann Meyer6, Holger Maul7, Britta Eiz-Vesper8, Andreas Krueger9, Axel Schambach6,10, Marcel Rm van den Brink2, Martin G Sauer1.   

Abstract

The transcription factor B cell CLL/lymphoma 11B (BCL11B) is indispensable for T lineage development of lymphoid progenitors. Here, we show that chimeric antigen receptor (CAR) expression during early phases of ex vivo generation of lymphoid progenitors suppressed BCL11B, leading to suppression of T cell-associated gene expression and acquisition of NK cell-like properties. Upon adoptive transfer into hematopoietic stem cell transplant recipients, CAR-expressing lymphoid progenitors differentiated into CAR-induced killer (CARiK) cells that mediated potent antigen-directed antileukemic activity even across MHC barriers. CD28 and active immunoreceptor tyrosine-based activation motifs were critical for a functional CARiK phenotype. These results give important insights into differentiation of murine and human lymphoid progenitors driven by synthetic CAR transgene expression and encourage further evaluation of ex vivo-generated CARiK cells for targeted immunotherapy.

Entities:  

Keywords:  Immunology; Immunotherapy; Leukemias; T cell development; Transplantation

Mesh:

Substances:

Year:  2019        PMID: 31479431      PMCID: PMC6877334          DOI: 10.1172/JCI126350

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  50 in total

1.  Retroviral and transposon-based tet-regulated all-in-one vectors with reduced background expression and improved dynamic range.

Authors:  Niels Heinz; Axel Schambach; Melanie Galla; Tobias Maetzig; Christopher Baum; Rainer Loew; Bernhard Schiedlmeier
Journal:  Hum Gene Ther       Date:  2010-12-19       Impact factor: 5.695

2.  Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.

Authors:  James N Kochenderfer; Steven A Feldman; Yangbing Zhao; Hui Xu; Mary A Black; Richard A Morgan; Wyndham H Wilson; Steven A Rosenberg
Journal:  J Immunother       Date:  2009-09       Impact factor: 4.456

3.  Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.

Authors:  Johannes L Zakrzewski; David Suh; John C Markley; Odette M Smith; Christopher King; Gabrielle L Goldberg; Robert Jenq; Amanda M Holland; Jeremy Grubin; Javier Cabrera-Perez; Renier J Brentjens; Sydney X Lu; Gabrielle Rizzuto; Derek B Sant'Angelo; Isabelle Riviere; Michel Sadelain; Glenn Heller; Juan Carlos Zúñiga-Pflücker; Chen Lu; Marcel R M van den Brink
Journal:  Nat Biotechnol       Date:  2008-03-30       Impact factor: 54.908

4.  An early T cell lineage commitment checkpoint dependent on the transcription factor Bcl11b.

Authors:  Long Li; Mark Leid; Ellen V Rothenberg
Journal:  Science       Date:  2010-07-02       Impact factor: 47.728

5.  Different thresholds of Notch signaling bias human precursor cells toward B-, NK-, monocytic/dendritic-, or T-cell lineage in thymus microenvironment.

Authors:  Magda De Smedt; Inge Hoebeke; Katia Reynvoet; Georges Leclercq; Jean Plum
Journal:  Blood       Date:  2005-07-19       Impact factor: 22.113

6.  Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.

Authors:  James N Kochenderfer; Zhiya Yu; Dorina Frasheri; Nicholas P Restifo; Steven A Rosenberg
Journal:  Blood       Date:  2010-07-14       Impact factor: 22.113

7.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

8.  New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling.

Authors:  Willem A Dik; Karin Pike-Overzet; Floor Weerkamp; Dick de Ridder; Edwin F E de Haas; Miranda R M Baert; Peter van der Spek; Esther E L Koster; Marcel J T Reinders; Jacques J M van Dongen; Anton W Langerak; Frank J T Staal
Journal:  J Exp Med       Date:  2005-05-31       Impact factor: 14.307

9.  4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.

Authors:  Adrienne H Long; Waleed M Haso; Jack F Shern; Kelsey M Wanhainen; Meera Murgai; Maria Ingaramo; Jillian P Smith; Alec J Walker; M Eric Kohler; Vikas R Venkateshwara; Rosandra N Kaplan; George H Patterson; Terry J Fry; Rimas J Orentas; Crystal L Mackall
Journal:  Nat Med       Date:  2015-05-04       Impact factor: 53.440

10.  The transcription factor E4bp4/Nfil3 controls commitment to the NK lineage and directly regulates Eomes and Id2 expression.

Authors:  Victoria Male; Ilaria Nisoli; Tomasz Kostrzewski; David S J Allan; James R Carlyle; Graham M Lord; Andreas Wack; Hugh J M Brady
Journal:  J Exp Med       Date:  2014-03-24       Impact factor: 14.307

View more
  9 in total

Review 1.  Recent advances and discoveries in the mechanisms and functions of CAR T cells.

Authors:  Rebecca C Larson; Marcela V Maus
Journal:  Nat Rev Cancer       Date:  2021-01-22       Impact factor: 60.716

Review 2.  The role of the thymus in allogeneic bone marrow transplantation and the recovery of the peripheral T-cell compartment.

Authors:  Enrico Velardi; Emmanuel Clave; Franco Locatelli; Antoine Toubert; Lucas C M Arruda; Francesca Benini
Journal:  Semin Immunopathol       Date:  2021-01-08       Impact factor: 9.623

3.  Adding chimeric antigen receptor-induced killer cells to the medical oncology shelf.

Authors:  Brigett D Brandjes; Marco L Davila
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

4.  Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.

Authors:  Sjoukje J C van der Stegen; Pieter L Lindenbergh; Roseanna M Petrovic; Hongyao Xie; Mame P Diop; Vera Alexeeva; Yuzhe Shi; Jorge Mansilla-Soto; Mohamad Hamieh; Justin Eyquem; Annalisa Cabriolu; Xiuyan Wang; Ramzey Abujarour; Tom Lee; Raedun Clarke; Bahram Valamehr; Maria Themeli; Isabelle Riviere; Michel Sadelain
Journal:  Nat Biomed Eng       Date:  2022-08-08       Impact factor: 29.234

5.  Sleeping Beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities.

Authors:  Chiara F Magnani; Giuseppe Gaipa; Federico Lussana; Daniela Belotti; Giuseppe Gritti; Sara Napolitano; Giada Matera; Benedetta Cabiati; Chiara Buracchi; Gianmaria Borleri; Grazia Fazio; Silvia Zaninelli; Sarah Tettamanti; Stefania Cesana; Valentina Colombo; Michele Quaroni; Giovanni Cazzaniga; Attilio Rovelli; Ettore Biagi; Stefania Galimberti; Andrea Calabria; Fabrizio Benedicenti; Eugenio Montini; Silvia Ferrari; Martino Introna; Adriana Balduzzi; Maria Grazia Valsecchi; Giuseppe Dastoli; Alessandro Rambaldi; Andrea Biondi
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 6.  Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.

Authors:  Michael A Morgan; Hildegard Büning; Martin Sauer; Axel Schambach
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

7.  Multi-objective optimization reveals time- and dose-dependent inflammatory cytokine-mediated regulation of human stem cell derived T-cell development.

Authors:  John M Edgar; Yale S Michaels; Peter W Zandstra
Journal:  NPJ Regen Med       Date:  2022-01-27

Review 8.  Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors.

Authors:  Tao Yu; Shao-Kun Yu; Yan Xiang; Kai-Hua Lu; Ming Sun
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

9.  Human induced-T-to-natural killer cells have potent anti-tumour activities.

Authors:  Zhiwu Jiang; Le Qin; Yuou Tang; Rui Liao; Jingxuan Shi; Bingjia He; Shanglin Li; Diwei Zheng; Yuanbin Cui; Qiting Wu; Youguo Long; Yao Yao; Zhihui Wei; Qilan Hong; Yi Wu; Yuanbang Mai; Shixue Gou; Xiaoping Li; Robert Weinkove; Sam Norton; Wei Luo; Weineng Feng; Hongsheng Zhou; Qifa Liu; Jiekai Chen; Liangxue Lai; Xinwen Chen; Duanqing Pei; Thomas Graf; Xingguo Liu; Yangqiu Li; Pentao Liu; Zhenfeng Zhang; Peng Li
Journal:  Biomark Res       Date:  2022-03-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.